The other "x" factor here is that the melanoma cohort should be far along by now------no one is even thinking about that study in Portland.
If interim results are excellent then I would say an educated decision could be made to invest, not bet. The results have to be good---after the Cohort 2 disaster, they can't be so stupid as to make the same mistake. If they are then this stock deserves to drop to $1.
I, for one, have NO INTENTION of taking any money out of my pocket until I see the FINAL TEST RESULTS of Cohort 3; you're placing a bet, not INVESTING, if you buy based on interim results which will only be a teaser, presented at a conference
I found this one - GALT has nothing to do with Ebola but its a pretty good article.
Nov 9th abstract presentation will give us the first look at Cohort 3 results although final results aren't expected until late November or early December. No date has been announced yet.